NCT04215653Unknown3 期
A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 448
- 主要终点
- The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.
研究概览
简要总结
A phase 3,double-blinded, double dummy, parallel, non-inferiority, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70 years, male and female
- •Has endoscopic diagnosis of active duodenal ulcer(s) (A1 or A2 stage) within 7 days prior to randomization
- •1 or 2 ulcers, 3-15 mm in diameter.
- •Signed informed concent form
排除标准
- •Has malignancy ulcer or malignancy ulcer not excluded, compouned ulcer, stress ulcer, esophageal erosion and ulcer, reflux esophagitis, Zollinger-Ellison syndrome.
- •Has esophageal and gastric varices；
- •With severe compliaction, such as pyloric obstruction, bleeding (Forrest I, IIa and IIb) or perforation, and etc；
- •Has gastric ulcer, or has history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)；
- •Has undergone surgical resection or partly resection of esophageal, stomach or duodenum；
- •Has used Proton Pump Inhibitors(PPIs) within 5 days prior to randomization, or continuous more than 3 days of use of Proton Pump Inhibitors within 2 weeks prior to randomization；
- •Has been treated with triple or quandruple Helicobacter pylori eradication therapy included PPIs within 28 days prior to randomization；
- •Current use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) which may induce ulcer or ulceric bleeding or continuous more than 3 days of use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) within 28 days prior to randomization；
- •Laboratory tests performed in screning stage revealed Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): > 1.5 upper limit of normal (ULN);
- •Laboratory tests performed in screning stage revealed thyroid stimulating hormone (TSH) or free triiodothyronine (FT3) and free thyroxin ( FT4) : > upper limit of normal (ULN)；
- •Woman in pregnancy or lactation period；
- •Plan for pregancy or not willing to contracept with reliable contraception method during study period and within 90 days after the final time of investigational drug administratio；
- •Have alcohol abuse or drug abuse 1 years prior to screening；
- •Has hypersensitivity or allergy to investigatory drug, comparatory drug or related supplements；
- •Has participated or been participating other clinical trials(non-interventional study is excluded)；
- •Has an uncotroled disease, such as has a history of significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, gastrointestinal, or mental or psychological disorders with drug treatment that,in the opinion of the investigator, would not be suitable for participating this clinical trial.
- •Has a history of malignancy or was treated or not treated for malignancy within 5 years before randomization (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma), no matter if there is evidence for local relapse or metastasis；
- •Laboratory tests performed in screning stage revealed estimated Glomerular filtration rate（eGFR） <80 mL/min/1.73 m2 calculated by Modification of Diet in Renal Disease(MDRD) equation；
- •In the opinion of the investigator, the patients with other situation would not be suitable for participating this clinical trial.
研究组 & 干预措施
Anaprazole Sodium + Rabeprazole Placebo
Experimental
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Anaprazole Sodium (Drug)
Anaprazole Sodium + Rabeprazole Placebo
Experimental
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Rabeprazole Placebo (Drug)
Rabeprazole +Anaprazole Sodium Placebo
Active Comparator
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Rabeprazole (Drug)
Rabeprazole +Anaprazole Sodium Placebo
Active Comparator
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Anaprazole Sodium Placebo (Drug)
结局指标
主要结局
The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.
时间窗: Treatment of 4 weeks
The endoscopic ulcer healing rate is defined as the percentage of patients healed (complete healing and significant response) in whom the endoscopic response of duodenal ulcers at week 4 has been evaluated by blinded independency central reading.
次要结局
- The endoscopic healing rate of duodenal ulcers at week 4, evaluated by investigator reading.(Treatment of 4 weeks)
研究者
相似试验
已完成
3 期
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsUlcerative ColitisNCT02136069Hoffmann-La Roche397
已完成
2 期
A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.Duodenal Ulcer，DUNCT04503629Sihuan Pharmaceutical Holdings Group Ltd.150
已完成
3 期
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid DependenceOpioid Use DisordersNCT02651584Braeburn Pharmaceuticals428
撤回
3 期
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With OverweightOverweightObesityNCT05209984Eurofarma Laboratorios S.A.1,855
已完成
3 期
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis PatientGastritis AcuteGastritis ChronicNCT05163756Daewon Pharmaceutical Co., Ltd.332